Two JAK2 inhibitors, ruxolitinib and fedratinib, have been FDA approved for patients with intermediate and high-risk myelofibrosis, while ruxolitinib is also approved for hydroxyurea intolerant PV patients. The gene discussed is JAK2; the disease is myelofibrosis.